The Mouse Monoclonal anti-DLL4 antibody has been validated for FACS and Func. It is suitable to detect DLL4 in samples from Human. There are 3+ publications available.
The mouse monoclonal antibody MHD4-46 recognizes the extracellular domain of DLL4 (Delta-like ligand 4), a type I transmembrane protein which plays an important role in vascular development.
Cross-Reactivity (Details)
Human
Purification
Purified by protein-A affinity chromatography.
Purity
> 95 % (by SDS-PAGE)
Endotoxin Level
Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
Sekine, Koyanagi, Koyama, Hozumi, Chiba, Yagita: "Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes." in: Arthritis research & therapy, Vol. 14, Issue 2, pp. R45, (2012) (PubMed).
Oishi, Sunamura, Egawa, Motoi, Unno, Furukawa, Habib, Yagita: "Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer." in: Pancreas, Vol. 39, Issue 6, pp. 897-903, (2010) (PubMed).
Yamanda, Ebihara, Asada, Okazaki, Niu, Ebihara, Koyanagi, Yamaguchi, Yagita, Arai: "Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade." in: Blood, Vol. 113, Issue 15, pp. 3631-9, (2009) (PubMed).
Target
DLL4
(delta-Like 4 (DLL4))
Alternative Name
DLL4
Background
Delta like canonical Notch ligand 4,DLL4 (Delta-like 4) is one of five ligands of Notch receptors. It interacts with Notch1 and Notch4. DLL4 is up-regulated at sites of physiologic and pathologic angiogenesis, whereas its expression is low in most adult normal tissues. It is also highly expressed in human clear-cell renal carcinomas, bladder cancers, and breast cancers. Blocking the DLL4-Notch interaction seems to be a promissing therapeutic approach.,Delta like ligand 4, AOS6, canonical Notch ligand 4